- RGSE +39%.
- CNET +21% on entering into an agreement with Wuxi Jingtum Network Technology.
- AEMD +14% as validation has completed and the opposition period expired for European Patent Number 2591359.
- NFLX +11% on Q4 result.
- VSLR +10% on Trump administration tariffs .
- SUNW +8% on new U.S. tariffs.
- RMD +10% on Q2 result.
- FNJN +10% on FY17 result.
- TNXP +6% as U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 12/948,828 “Methods and compositions for treating symptoms associated with posttraumatic stress disorder using cyclobenzaprine,” covering the use of Tonmya*, or TNX-102 SL, for the treatment of posttraumatic stress disorder.
- AMRN +8% on announcement that the large-scale REDUCE-IT cardiovascular outcomes study supporting Vascepa (icosapent ethyl) has reported more than 90% of the targeted 1,612 primary major adverse cardiovascular events.
- INSY +7%.
- CRSP +7% on positive analyst action.
- LOGI +6%.
- BLRX +6% as immunotherapy candidate AGI-134 shows positive effect in preclinical melanoma studies.
- ATI +5% on Q4 earning.
- SRNE +6% on acquisition of 1,801,801 shares of common stock and warrants to purchase up to 261,438 shares from a third party for a total of $11,531,526.40 ($6.40/share).
- ENPH +5%.
- Now read: Enphase Narrative Turns Positive But Problems Remain
Original article